5Bemardo A, Bali C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultra-large yon WiRe-brand factor multimers under flow [ J ]. Blood,2004,104 : 100 - 106.
6Vesely SK, George JN, Lammle B, et al. ADAMT13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome:relation to pres enting features and clinical outcomes in a prospectiv ecohort of 142 patients [ J ]. Blood, 2003,102 : 60 - 68.
2Peyvandi F, Palla R, Lotta L A. Pathogenesis and treat- ment of acquired idiopathic thrombotic thrombocytopenic purpura[ J ]. Haematologica, 2010,95 ( 9 ) : 1444-1447.
3George J N. Clinical practive. Thrombotic thrombocyto- penic purpura[J]. N Engl J Med, 2006,354(18) :1927- 1935.
4Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30- 1991.
5An 85-year-old woman with renal failure, neuro- logic deterioration, and seizures [ J ]. N Engl J Med, 1991,325(4) :265-273.
6Sadler J E. Biochemistry and genetis of yon Willebrand factor[J]. Annu Rev Biochem, 1998,67(4) :395-424.
7Fry D E, Pearlstein L, Fulton R L, et al. Multiple sys- tem organ failure. The role of uncontrolled infection[ J ]. Arch Surg, 1980,115(2) :136-140.
8Furlan M, Robles R, Galbusera M, et al. yon Wille- brand factor-cleaving protease in thrombotic thrombocyto- penic purpura and the hemolytic-uremic syndrome [ J]. NEngl J Med, 1998,339(22) :1578-1584.
9Shelat S G, Ai J, Zheng X L, et al. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS 13 proteo- lytic activity andinhibitor azsays[J]. Semin Thromb Hem- ost, 2005,31(6) :659-672.
10Gutterman L A, Kloster B, Tsai H M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura [ J ]. Blood Cells Mol Dis, 2002,28(3) :385-391.
